Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002353 · ClinicalTrials.gov registry record · Phase 1
A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects
A Phase 1 study, sponsored by United Biomedical.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002353: Completed Phase 1 study, sponsored by United Biomedical.
NCT00002353 is a Phase 1 study that has completed, run by United Biomedical. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002353, a Phase 1 study, has completed, sponsored by United Biomedical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To evaluate an HIV lipopeptide immunotherapeutic, P3C541b, at two dose levels administered subcutaneously in HIV-seropositive patients.
Interventions
- BIOLOGICAL P3C541b Lipopeptide
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002353
The ClinicalTrials.gov registry entry for NCT00002353 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is United Biomedical, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which P3C541b Lipopeptide is the first listed.
NCT00002353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002353 about?
NCT00002353 is a clinical study titled "A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects". To evaluate an HIV lipopeptide immunotherapeutic, P3C541b, at two dose levels administered subcutaneously in HIV-seropositive patients.
What is the current status of trial NCT00002353?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00002353?
The interventions under investigation include: P3C541b Lipopeptide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002353?
This trial is sponsored by United Biomedical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.